Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

The stock's rise snapped a four-day losing streak.

Instead, we used a more subjective (but more relevant) mix of: A good quality pipeline of innovative ... cancer early from a blood sample. Regeneron's main product is Duxipent, an autoimmune disease ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged ...

The upcoming report from Regeneron (REGN) is expected to reveal ... The combined assessment of analysts suggests that 'Revenues- Libtayo- Total' will likely reach $338.92 million.

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high estimate of ... LDL cholesterol lowering; Libtayo in oncology; and Kevzara ...

For 17-year-old Emma Wen, a senior at Great Neck North High School, the Regeneron Science Talent Search is more than a passion project. Most adults couldn't understand Wen's research, which could ...

The Regeneron Science Talent Search, a program of Society for Science since 1942, is the U.S.'s oldest and most prestigious science and math competition for high school seniors. Each year ...

competition for high school seniors. Now in its 84th year, the competition identifies extraordinary young minds who blend scientific talent, curiosity and bold leadership to drive meaningful change ...

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...

ABC has handed an early Season 2 renewal to its breakout new crime drama High Potential. The light procedural starring Kaitlin Olson joins ABC’s flagship comedy Abbott Elementary in securing a ...